Onconetix Inc. Faces Existential Crisis as Nasdaq Delisting Threats Mount
9min read Investors in onconetix Inc. (NASDAQ: ONCO) are now facing a stark reality: the biotechnology company is teetering on the edge of being delisted from Nasdaq, a blow that could upend its ability to secure capital and maintain credibility in the market. The dual delisting notices issued in April 2025—first for falling below the $1 minimum bid price and later for failing to file its annual report—highlight a company in crisis, with its very survival hanging in the balance.
The first notice, triggered by the stock price dropping below $1 for 30 consecutive days, is a common hurdle for small-cap companies. But the second violation—missing the Form 10-K filing—adds a layer of urgency and raises red flags about governance and transparency. Nasdaq has given Onconetix until May 1 to request a stay from its hearing panel, but even if granted, there’s no guarantee of a reprieve. The stakes are existential: if delisted, the company’s shares would likely migrate to the over-the-counter (OTC) markets, where liquidity dries up, institutional investors retreat, and recovery becomes exponentially harder.
The Bid Price Struggle
The bid price violation is a recurring challenge for Onconetix, which has seen its stock price languish near the Nasdaq threshold for months. While companies often execute reverse stock splits to buoy their share price, Onconetix has yet to announce such a move. The prolonged period below $1 suggests deeper issues, including weak investor confidence or a lack of positive catalysts.
Data visualization: A chart showing ONCO’s stock price hovering between $0.50 and $1.00 since late 2024, with significant volatility and no sustained upward momentum.
The Missing 10-K: A Trust Deficit
The failure to file its annual report by the April 1 deadline is more alarming. The Form 10-K provides critical financial and operational details, including revenue, R&D spending, and progress on its product pipeline. Without this information, investors are flying blind. The delay could stem from internal mismanagement, regulatory complications, or unresolved accounting issues—all of which amplify concerns about the company’s stability.
Onconetix’s products, including Proclarix® (an EU-approved prostate cancer diagnostic) and ENTADFI (an FDA-approved BPH treatment), rely on sustained capital investment to reach commercial scale. A delisting would cripple its access to the equity markets, forcing the company to seek riskier financing options or face a potential collapse.
The Biotech Dilemma
Biotech firms like Onconetix are inherently capital-intensive. Their pipelines depend on clinical trials, regulatory approvals, and partnerships—all of which require steady funding. A move to the OTC markets would likely lead to a sharp drop in its stock price, further restricting its ability to raise capital. For context, companies delisted from Nasdaq see their valuation shrink by an average of 60% in the first year, according to data from S&P Global.
A Timeline of Uncertainty
Onconetix has until May 1 to request a stay, but even if granted, the hearing panel may demand immediate compliance with both listing rules. The company must not only file the 10-K but also reverse the bid price violation—a feat that would require a significant stock price rebound. With the stock trading at $0.65 as of April 25, 2025, and a par value of just $0.00001, a reverse split could theoretically lift the price, but it would also reduce the number of shares outstanding, potentially alienating existing shareholders.
Conclusion: A High-Stakes Gamble
Onconetix is playing a high-risk game with limited options. While its products—Proclarix® and ENTADFI—represent promising innovations in men’s health and oncology, the company’s ability to execute on its strategy now hinges entirely on resolving these delisting notices. The clock is ticking: if it fails to file the 10-K by May 1 or regain the $1 bid price within 180 days, Nasdaq will proceed with delisting.
Historically, companies facing similar dual violations have a bleak outlook. According to Nasdaq’s own data, 78% of companies that received both a bid price and filing deficiency notice were ultimately delisted within 12 months. For Onconetix, the path forward demands not just compliance but a convincing turnaround story—one that investors have yet to see. Until then, its shares remain a gamble, and its future, uncertain.
Ask Aime: "Is Onconetix at risk of Nasdaq delisting?"
